Exploring DVAI for your organisation? Arrange a confidential, no-obligation discussion. Confidential discussion
Pharma Agents · Cluster 2 of 5

Manufacturing & quality (GxP)

The regulated production floor — batch-record review, instant SOP access, and tech-transfer parameter monitoring. Every agent here operates under a strict GxP boundary: it surfaces and flags, but never signs, approves or changes a regulated record.

Use case 504

Batch Production Record review & deviation triage

The pain point

Documentation deficiencies routinely top GMP inspection findings — across MHRA data, documentation and quality-system issues together account for close to half of all inspection findings,55 including missing signatures, unverified parameters and undocumented changes. Reviewing a single complex batch record can take Quality Assurance days, delaying product release.

GxP regulatory boundary. Within a GxP environment the MHRA/FDA boundary is absolute: this agent does not create, alter, delete or approve any regulated GxP record, and it gives no clinical or medical advice. It triages, summarises and surfaces information for the review and validated signature of a qualified human (21 CFR Part 11 / EudraLex Annex 11). Every regulated decision, and the integrity of every record, remains with the responsible person.
Impact — organisation

QA time absorbed by manual record review; delayed product release; documentation gaps that surface as inspection findings.

Impact — customer / client

For the market, slower release of medicines and, in the worst case, supply resilience risk.

How it’s addressed

The agent scans execution logs, cross-checks recorded parameters against the Master Recipe, and surfaces potential anomalies and non-conformances for QA review. Under 21 CFR Part 11 and EudraLex Annex 11, it cannot log, approve or sign off a CAPA or any regulated record — that requires the QA Manager’s validated digital signature.

The benefits
Organisation

Designed to speed the QA review by surfacing potential anomalies for a human to assess — supporting, never replacing, the qualified QA decision and signature the regulations require.

Customer / client

For the market, a more resilient supply of medicines released under unchanged human quality control.

Use case 506

GxP SOP query agent

The pain point

Operators and analysts work against thousands of pages of deeply-nested SOPs. When a hurdle arises, finding the correct directive takes time — and the delay tempts manual shortcuts that compromise the contemporaneous-recording rule at the heart of good documentation practice.

GxP regulatory boundary. Within a GxP environment the MHRA/FDA boundary is absolute: this agent does not create, alter, delete or approve any regulated GxP record, and it gives no clinical or medical advice. It triages, summarises and surfaces information for the review and validated signature of a qualified human (21 CFR Part 11 / EudraLex Annex 11). Every regulated decision, and the integrity of every record, remains with the responsible person.
Impact — organisation

Line stoppages while staff hunt for the right procedure; the compliance risk of shortcuts taken under time pressure; inconsistent procedure interpretation.

Impact — customer / client

For the market, quality risk whenever procedure is guessed at rather than followed.

How it’s addressed

The agent serves verbatim text from approved, version-controlled SOPs — by voice for cleanroom headsets or on screen — so staff get the right directive instantly. It is deliberately locked to reproduce approved text only: it does not generate, paraphrase or ad-lib guidance outside the official, controlled documents.

The benefits
Organisation

Designed to cut procedure-lookup delay by giving staff instant access to the exact approved text — never generating advice, only surfacing what the version-controlled SOP already says.

Customer / client

For inspectors and the market, clearer evidence of process control and consistent adherence.

Use case 510

Tech-transfer & manufacturing parameter monitor

The pain point

Moving a formulation from pilot scale to commercial production requires meticulous calibration of critical process parameters — temperature, agitation, pressure. Suboptimal settings lock a process into frequent deviations and waste.

GxP regulatory boundary. Within a GxP environment the MHRA/FDA boundary is absolute: this agent does not create, alter, delete or approve any regulated GxP record, and it gives no clinical or medical advice. It triages, summarises and surfaces information for the review and validated signature of a qualified human (21 CFR Part 11 / EudraLex Annex 11). Every regulated decision, and the integrity of every record, remains with the responsible person.
Impact — organisation

Deviation-prone processes when parameters are not well-tuned at transfer; revalidation cost; yield and waste penalties.

Impact — customer / client

For the market, supply and cost pressure from an inefficient process.

How it’s addressed

The agent evaluates historical pilot runs against real-time manufacturing data and suggests optimal running bounds to the plant engineers. It is a monitoring and advisory layer only — any change to a production setpoint runs through formal change control and manual engineering intervention.

The benefits
Organisation

Designed to support a smoother, lower-deviation tech transfer by surfacing optimal parameter bounds — with every setpoint change remaining under formal change control and human decision.

Customer / client

For the market, improved production stability and reduced waste, under unchanged change-control discipline.

Previous cluster Discovery & clinical trials

See how these map onto your organisation. Request a confidential discussion.

Get started
Confidential discussion

Talk to our Customer Success Team.

Take it further with a confidential, no-obligation discussion to scope a pilot in your environment.

Private & no-obligation

Every enquiry is held in confidence. We’ll walk you through the use cases relevant to you and scope how a sovereign deployment would work in your environment — with no obligation to proceed.

Request a meeting with the CST

We aim to respond within one working day.

Held in confidence · no obligation

Sources & references

Statistics describe demand and conditions across the relevant sector and are drawn from the cited public sources. They characterise the sector-level problem these agents address; they are not performance claims for any DVAI product. Deep Voice AI Limited is a pre-revenue company and makes no representation as to outcomes for any individual organisation. Figures are current as at the date of the cited publications.

Capable AI, on your terms — not the cloud’s.

Products
Business Agents
Company
Legal